Company intelligence / Profile preview

Sovran Bio

United States

Ownership: Private
Development stage: Other

Overview

Sovran Bio is developing novel biologic approaches for precise cancer cell targeting, focusing on broad-spectrum targeting in oncology and autoimmunity. They have entered into a strategic partnership with Escugen to accelerate development of multiple antibody and ADC therapeutics.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyAntibody-drug conjugateBiologic
Industry: Biotech

Partnerships

Escugen

Beyond the preview

Go deeper on Sovran Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sovran Bio.

Explore the full profile